RNS Number : 8244N
Cellular Goods PLC
04 October 2021
 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Press release

4 October 2021

 

Cellular Goods PLC

("Cellular Goods" or "the Company")

 

Director dealings & TR1 notification

 

Cellular Goods (LSE: CBX), a UK-based provider of premium consumer products formulated with lab-made cannabinoids, announces that Alexis Abraham, chief executive, purchased two million ordinary shares in the Company at 7.75 pence each on 1 October 2021.

The acquisition has increased his total holding to 20.5 million shares, representing 4.1% of the issued capital in the Company, as per the notification below.

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Cellular Goods plc

LEI: 213800IXPX4Z2MKX2U28

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)



2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments


An event changing the breakdown of voting rights


Other (please specify)iii:


3. Details of person subject to the notification obligationiv

Name

Alexis Abraham, CEO

City and country of registered office (if applicable)


4. Full name of shareholder(s) (if different from 3.)v

Name


City and country of registered office (if applicable)


5. Date on which the threshold was crossed or reachedvi:

1 Oct. 2021

6. Date on which issuer notified (DD/MM/YYYY):

1 Oct. 2021

7. Total positions of person(s) subject to the notification obligation


% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.1%

   n/a


504,750,000

Position of previous notification (if

applicable)

3.7%

   n/a

 3.7%

504,750,000

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BK964W87

20,500,000

  n/a

4.1%

 n/a











SUBTOTAL 8. A

20,500,000

4.1%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights


















SUBTOTAL 8. B 1

  n/a

  n/a

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights






















SUBTOTAL 8.B.2

  n/a

   n/a

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
xiv (please add additional rows as necessary)


Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold






















10. In case of proxy voting, please identify:

Name of the proxy holder


The number and % of voting rights held


The date until which the voting rights will be held



11. Additional informationxvi


 

Place of completion

London, UK

Date of completion

2 Oct. 2021

 

 

For further information please contact:

 

Cellular Goods


Alexis Abraham

Chief Executive

Neil Thapar

Investor Relations

+44 207 031 6871

 

 

+44 787 645 5323

Tennyson Securities


Corporate Broker

Peter Krens

 

+44 207 186 9030

Novum Securities


Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427 

Tancredi Intelligent Communication


Media Relations

Helen Humphrey

Edward Daly

Salamander Davoudi

cellulargoods@tancredigroup.com

 

+44 744 922 6720

+44 786 143 0057

+44 795 754 9906

 

About Cellular Goods PLC

 

Cellular Goods is a U.K.-based provider of premium consumer products incorporating lab-made cannabinoids. It was established in August 2018 to develop and market efficacy-led and research-backed cannabinoid products. The initial focus is on three categories: premium CBG skincare, CBD ingestibles, and CBD topical athletic recovery formulas. The first products will launch December 2021 and be available direct to consumers through the Company's website.

www.cellulargoods.co 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFVEISLVIIL